Good morning. My name is Jean-Luc Urbain. I am the president of the Canadian Association of Nuclear Medicine.
I'd like to thank the committee for inviting me once again to testify on rare disorders and medical isotopes. We have significant issues, besides the big issue we have been dealing with over the last year. It turns out that we are now facing another significant crisis, due to the lack of authorization for isotopes that we need to treat patients with rare disorders. So I'm very pleased to be here this morning.